IP Library Granted Patent US 12673111
Granted Patent B2
US 12673111 · App. 19/060,384 · Granted Jul 7, 2026

Bifunctional degraders of galactose-deficient immunoglobulins

Inventors: Gene M. Dubowchik (Killingworth, CT); Ada Vaill (Salem, CT); Reese M. Caldwell (Cambridge, MA); Brian M. Linhares (Bedford, MA); David K. Leahy (Marblehead, MA); James Bryson (Asheville, NC); Lawrence R. Marcin (Bethany, CT)
Assignee: Biohaven Therapeutics Ltd.
A61K47/6807A61K31/7008C07K16/283
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673111
App. No.
19/060,384
Granted
Jul 7, 2026
Kind
B2
Abstract

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.

Claims (35)

1 . A composition of matter having the chemical formula [AGN101]:

wherein,

 is a galactose-deficient Immunoglobulin A1 (Gd-IgA1) binding moiety comprising a heavy chain comprising the polypeptide sequences of SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, and a light chain comprising the polypeptide sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14;

 is a cellular receptor-binding moiety comprising an N-acetyl-D-galactosamine (GalNAc) group; and

L is a linking group,

a is 1, b is 1, 2, or 3, and c is 1 or 2.

2 . The composition of matter of claim 1 , wherein

comprises a heavy chain polypeptide sequence of SEQ ID NO: 1 and light chain polypeptide sequence SEQ ID NO: 2.

3 . The composition of matter of claim 1 , wherein

comprises a heavy chain polypeptide sequence of SEQ ID NO: 3 and light chain polypeptide sequence SEQ ID NO: 2.

4 . The composition of matter of claim 1 , wherein

comprises a heavy chain polypeptide sequence of SEQ ID NO: 4 and light chain polypeptide sequence SEQ ID NO: 2.

5 . The composition of matter of claim 1 , wherein L comprises one or more —(O)C—[(CH 2 ) n O] m (CH 2 ) n NH—, —[(CH 2 ) n O] m NHC(O)[(CH 2 ) n O] m NH—, and —[(CH 2 ) n O] m {NHC(O)[(CH 2 ) n O] m } p NH—, wherein each m and n are independently 1 to 10.

6 . The composition of matter of claim 1 , wherein L comprises one or more —[(CH 2 ) n —O] m —, wherein each m and n are independently 1 to 10.

7 . The composition of matter of claim 1 , wherein L comprises —(CH 2 ) n —O—(CH 2 CH 2 O) n —(CH 2 ) n —, wherein each n is independently 1-10.

8 . The composition of matter of claim 1 , wherein

comprises an IgG1 heavy chain that is connected to L at an amino acid residue selected from K246 and K248 of the IgG1 heavy chain according to the EU numbering scheme.

9 . The composition of matter of claim 8 , wherein

is connected to L at the amino acid residue K248 of the IgG1 heavy chain.

10 . The composition of matter of claim 1 , wherein b is 3, and each

comprises an N-acetyl-D-galactosamine (GalNAc) group.

11 . The composition of matter of claim 1 , wherein b is 3, and

comprises the chemical formula:

wherein,

Z B is absent, —(CH 2 ) IM —, —C(═O)—(CH 2 ) IM —, or —C(═O)—(CH 2 ) IM —NR M —;

R M is H or C 1 -C 3 alkyl; and

each occurrence of IM is independently 1, 2, or 3.

12 . The composition of matter of claim 1 , wherein b is 2 or 3, ar

has the chemical formula [MAT01A], [MAT01B], [MAT01C], or [MAT01D]:

13 . The composition of matter of claim 1 , wherein c is 2.

14 . The composition of matter of claim 1 , wherein a is 1, b is 3, c is 2, each

has the chemical formula [MAT01A]:

and

wherein

comprises an IgG1 heavy chain that is connected to respective L at an amino acid residue selected from K246 and K248 of the IgG1 heavy chain according to the EU numbering scheme.